Bacillus licheniformis Zhengchangsheng® Inhibits Obesity by Regulating the AMP-Activated Protein Kinase Signaling Pathway

doi:10.1007/s12602-021-09792-6

. 2021 Dec;13(6):1658-1667.

doi: 10.1007/s12602-021-09792-6. Epub 2021 May 5.

Bacillus licheniformis Zhengchangsheng® Inhibits Obesity by Regulating the AMP-Activated Protein Kinase Signaling Pathway

Xiaojie Lu^#¹, Yue Jing^#¹, Xiaofei Zhou¹, Naisheng Zhang¹, Jiandong Tai², Yongguo Cao³

Affiliations

¹ Department of Clinical Veterinary Medicine, College of Veterinary Medicine, Jilin University, Changchun, 130062, People's Republic of China.
² Department of Colorectal and Anal Surgery, The First Hospital of Jilin University, Changchun, 130021, People's Republic of China.
³ Department of Clinical Veterinary Medicine, College of Veterinary Medicine, Jilin University, Changchun, 130062, People's Republic of China. ygcao82@jlu.edu.cn.

^# Contributed equally.

PMID: 33954883
DOI: 10.1007/s12602-021-09792-6

Bacillus licheniformis Zhengchangsheng® Inhibits Obesity by Regulating the AMP-Activated Protein Kinase Signaling Pathway

Xiaojie Lu et al. Probiotics Antimicrob Proteins. 2021 Dec.

. 2021 Dec;13(6):1658-1667.

doi: 10.1007/s12602-021-09792-6. Epub 2021 May 5.

Authors

Xiaojie Lu^#¹, Yue Jing^#¹, Xiaofei Zhou¹, Naisheng Zhang¹, Jiandong Tai², Yongguo Cao³

Affiliations

¹ Department of Clinical Veterinary Medicine, College of Veterinary Medicine, Jilin University, Changchun, 130062, People's Republic of China.
² Department of Colorectal and Anal Surgery, The First Hospital of Jilin University, Changchun, 130021, People's Republic of China.
³ Department of Clinical Veterinary Medicine, College of Veterinary Medicine, Jilin University, Changchun, 130062, People's Republic of China. ygcao82@jlu.edu.cn.

^# Contributed equally.

PMID: 33954883
DOI: 10.1007/s12602-021-09792-6

Abstract

As a metabolic syndrome, obesity has become a global public health problem. Bacillus licheniformis has been shown to inhibit obesity by regulating the gut microbiota, but the underlying mechanism of its therapeutic effect is still unknown. In this study, the anti-obesity mechanism of Bacillus licheniformis Zhengchangsheng® was investigated by examining a high-fat diet-induced obesity mouse model. Our results showed that Bacillus licheniformis Zhengchangsheng® significantly decreased body weight gain and fat accumulation, serum lipid profiles, and proinflammatory cytokine levels and improved glucose and lipid metabolism in obese mice. Furthermore, compared with those of high-fat diet-fed mice, Bacillus licheniformis Zhengchangsheng® treatment also inhibited nuclear factor-κB activation, increased phosphorylated AMP-activated protein kinase activation in the liver, and regulated the expression of genes associated with lipid metabolism. These results indicated that Bacillus licheniformis Zhengchangsheng®-induced obesity inhibition could occur by activating the AMP-activated protein kinase signaling pathway. Thus, our results suggested that Bacillus licheniformis Zhengchangsheng® has the potential to treat obesity and related metabolic diseases in the clinic.

Keywords: AMPK; Bacillus licheniformis; Lipid metabolism; NF-κB; Obesity.

PubMed Disclaimer

Cited by

The Effects of Probiotic Bacillus Spores on Dexamethasone-Treated Rats.
Inceu AI, Neag MA, Catinean A, Bocsan CI, Craciun CI, Melincovici CS, Muntean DM, Onofrei MM, Pop RM, Buzoianu AD. Inceu AI, et al. Int J Mol Sci. 2023 Oct 12;24(20):15111. doi: 10.3390/ijms242015111. Int J Mol Sci. 2023. PMID: 37894792 Free PMC article.
Biotechnological and food synthetic biology potential of platform strain: Bacillus licheniformis.
He H, Yu Q, Ding Z, Zhang L, Shi G, Li Y. He H, et al. Synth Syst Biotechnol. 2023 Mar 30;8(2):281-291. doi: 10.1016/j.synbio.2023.03.008. eCollection 2023 Jun. Synth Syst Biotechnol. 2023. PMID: 37090063 Free PMC article. Review.
Encouraging Tactics with Genetically Modified Probiotics to Improve Immunity for the Prevention of Immune-Related Diseases including Cardio-Metabolic Disorders.
Asai T, Yoshikawa S, Ikeda Y, Taniguchi K, Sawamura H, Tsuji A, Matsuda S. Asai T, et al. Biomolecules. 2022 Dec 21;13(1):10. doi: 10.3390/biom13010010. Biomolecules. 2022. PMID: 36671395 Free PMC article.
Brevibacillus laterosporus BL1, a promising probiotic, prevents obesity and modulates gut microbiota in mice fed a high-fat diet.
Weng G, Huang J, Ma X, Song M, Yin Y, Deng D, Deng J. Weng G, et al. Front Nutr. 2022 Nov 24;9:1050025. doi: 10.3389/fnut.2022.1050025. eCollection 2022. Front Nutr. 2022. PMID: 36505236 Free PMC article.
Microbiota Modulation in Patients with Metabolic Syndrome.
Araujo R, Borges-Canha M, Pimentel-Nunes P. Araujo R, et al. Nutrients. 2022 Oct 25;14(21):4490. doi: 10.3390/nu14214490. Nutrients. 2022. PMID: 36364752 Free PMC article. Review.

See all "Cited by" articles

References

1. Ng M, Fleming T, Robinson M et al (2014) Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the global burden of disease study 2013. Lancet 384(9945):766–781. https://doi.org/10.1016/S0140-6736(14)60460-8 - DOI - PubMed - PMC
1. Gu DF, Reynolds K, Wu XG, Chen F, Duan XF, Reynolds RF, Whelton PK, He J, Grp IC (2005) Prevalence of the metabolic syndrome and overweight among adults in China. Lancet 365(9468):1398–1405. https://doi.org/10.1016/S0140-6736(05)66375-1 - DOI - PubMed
1. Yu Y, Cai JJ, She ZG, Li HL (2019) Insights into the epidemiology, pathogenesis, and therapeutics of nonalcoholic fatty liver diseases. Adv Sci 6 (4). https://doi.org/10.1002/advs.201801585
1. Tanaka N, Kimura T, Fujimori N, Nagaya T, Komatsu M, Tanaka E (2019) Current status, problems, and perspectives of non-alcoholic fatty liver disease research. World J Gastroenterol 25(2):163–177. https://doi.org/10.3748/wjg.v25.i2.163 - DOI - PubMed - PMC
1. Cani PD, Bibiloni R, Knauf C, Waget A, Neyrinck AM, Delzenne NM, Burcelin R (2008) Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 57(6):1470–1481. https://doi.org/10.2337/db07-1403 - DOI - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Springer
Medical
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program

[1] Ng M, Fleming T, Robinson M et al (2014) Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the global burden of disease study 2013. Lancet 384(9945):766–781. https://doi.org/10.1016/S0140-6736(14)60460-8 - DOI - PubMed - PMC

[2] Ng M, Fleming T, Robinson M et al (2014) Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the global burden of disease study 2013. Lancet 384(9945):766–781. https://doi.org/10.1016/S0140-6736(14)60460-8 - DOI - PubMed - PMC

[3] Gu DF, Reynolds K, Wu XG, Chen F, Duan XF, Reynolds RF, Whelton PK, He J, Grp IC (2005) Prevalence of the metabolic syndrome and overweight among adults in China. Lancet 365(9468):1398–1405. https://doi.org/10.1016/S0140-6736(05)66375-1 - DOI - PubMed

[4] Gu DF, Reynolds K, Wu XG, Chen F, Duan XF, Reynolds RF, Whelton PK, He J, Grp IC (2005) Prevalence of the metabolic syndrome and overweight among adults in China. Lancet 365(9468):1398–1405. https://doi.org/10.1016/S0140-6736(05)66375-1 - DOI - PubMed

[5] Yu Y, Cai JJ, She ZG, Li HL (2019) Insights into the epidemiology, pathogenesis, and therapeutics of nonalcoholic fatty liver diseases. Adv Sci 6 (4). https://doi.org/10.1002/advs.201801585

[6] Yu Y, Cai JJ, She ZG, Li HL (2019) Insights into the epidemiology, pathogenesis, and therapeutics of nonalcoholic fatty liver diseases. Adv Sci 6 (4). https://doi.org/10.1002/advs.201801585

[7] Tanaka N, Kimura T, Fujimori N, Nagaya T, Komatsu M, Tanaka E (2019) Current status, problems, and perspectives of non-alcoholic fatty liver disease research. World J Gastroenterol 25(2):163–177. https://doi.org/10.3748/wjg.v25.i2.163 - DOI - PubMed - PMC

[8] Tanaka N, Kimura T, Fujimori N, Nagaya T, Komatsu M, Tanaka E (2019) Current status, problems, and perspectives of non-alcoholic fatty liver disease research. World J Gastroenterol 25(2):163–177. https://doi.org/10.3748/wjg.v25.i2.163 - DOI - PubMed - PMC

[9] Cani PD, Bibiloni R, Knauf C, Waget A, Neyrinck AM, Delzenne NM, Burcelin R (2008) Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 57(6):1470–1481. https://doi.org/10.2337/db07-1403 - DOI - PubMed

[10] Cani PD, Bibiloni R, Knauf C, Waget A, Neyrinck AM, Delzenne NM, Burcelin R (2008) Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 57(6):1470–1481. https://doi.org/10.2337/db07-1403 - DOI - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Bacillus licheniformis Zhengchangsheng® Inhibits Obesity by Regulating the AMP-Activated Protein Kinase Signaling Pathway

Affiliations

Bacillus licheniformis Zhengchangsheng® Inhibits Obesity by Regulating the AMP-Activated Protein Kinase Signaling Pathway

Authors

Affiliations

Abstract

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Research Materials

Abstract

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources

Medical

Research Materials